HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Staphylococcal Skin Infections

Subscribe to New Research on Staphylococcal Skin Infections

Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.

Also Known As:

Infections, Staphylococcal Skin; Skin Infections, Staphylococcal; Staphylococcal Diseases, Skin; Staphylococcal Infections, Skin; Staphylococcal Skin Diseases; Disease, Staphylococcal Skin; Diseases, Staphylococcal Skin; Infection, Staphylococcal Skin; Skin Disease, Staphylococcal; Skin Infection, Staphylococcal; Skin Staphylococcal Disease; Skin Staphylococcal Diseases; Skin Staphylococcal Infection; Skin Staphylococcal Infections; Staphylococcal Disease, Skin; Staphylococcal Infection, Skin; Staphylococcal Skin Disease; Staphylococcal Skin Infection; Skin Diseases, Staphylococcal

Networked: 39 relevant articles (4 outcomes, 1 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Infection
2.	Thymoma (Thymic Carcinoma)
3.	Job's Syndrome (Hyper-IgE Syndrome)
4.	Candidiasis (Moniliasis)
5.	Congenital Nystagmus

Experts

1.	Seleem, Mohamed N: 3 articles (01/2015 - 01/2014)
2.	Thangamani, Shankar: 2 articles (01/2015 - 01/2015)
3.	Browne, Sarah K: 2 articles (01/2014 - 12/2010)
4.	Clark, R J: 1 article (04/2015)
5.	Daly, N L: 1 article (04/2015)
6.	Fensterseifer, I C M: 1 article (04/2015)
7.	Silva, O N: 1 article (04/2015)
8.	Franco, O L: 1 article (04/2015)
9.	Malik, U: 1 article (04/2015)
10.	Craik, D J: 1 article (04/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Staphylococcal Skin Infections:

1.	PeptidesIBA 01/01/2014 - "The therapeutic efficacy of two novel short antimicrobial and anti-inflammatory peptides (RR and RRIKA) was evaluated in a mouse model of staphylococcal skin infection. " 09/01/2013 - "Peptides are very promising agents for the topical treatment of staphylococcal skin infections. " 04/01/2015 - "In vivo efficacy of anuran trypsin inhibitory peptides against staphylococcal skin infection and the impact of peptide cyclization."
2.	TrypsinIBA 04/01/2015 - "In vivo efficacy of anuran trypsin inhibitory peptides against staphylococcal skin infection and the impact of peptide cyclization."
3.	ebselenIBA 01/01/2015 - "The therapeutic efficacy of ebselen was evaluated in a mouse model of staphylococcal skin infections. "
4.	polyprolineIBA 01/01/2015 - "Antibacterial activity and therapeutic efficacy of Fl-P(R)P(R)P(L)-5, a cationic amphiphilic polyproline helix, in a mouse model of staphylococcal skin infection."
5.	Clindamycin (Cleocin)FDA LinkGeneric 11/11/1988 - "We conducted a double-blind, controlled trial of low-dose (150 mg/d) oral clindamycin hydrochloride vs placebo to prevent recurrent staphylococcal skin infections. " 03/01/2000 - "In patients with numerous staphylococcal skin infections, oral clindamycin 150 mg every day for 3 months safely reduces further episodes. " 11/11/1988 - "We conclude that a three-month course of low-dose oral clindamycin is an effective, convenient, well-tolerated, and often durable approach to prevention of recurrent staphylococcal skin infections." 11/11/1988 - "Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy." 03/10/1989 - "Clindamycin for staphylococcal skin infections in AIDS."
6.	Immunoglobulin E (IgE)IBA 05/17/1980 - "An 8-year old girl suffering from chronic relapsing staphylococcal skin infection since the first days of life was found to have extremely high (up to 26,500 units/ml) serum IgE levels and impaired polymorphonuclear chemotaxis. " 05/01/1978 - "A 24-year old woman had the major features of the hyperimmunoglobulin E syndrome: recurrent staphylococcal skin infections (from the age of 6 months), an extremely elevated serum immunoglobulin E level (25,000 units/ml), and defective neutrophil chemotaxis. " 06/01/2000 - "Congenital immunodeficiency in hyper IgE syndrome is characterised by a markedly raised IgE level, recurrent staphylococcal skin infection and pneumatoceles. " 06/01/1981 - "Anti-S, aureus IgE binding was significantly higher in three groups of patients (those with eczema, those with or without series staphylococcal abscesses, and allergic patients with staphylococcal skin infections) than it was in the control group. " 08/01/1994 - "Dogs with idiopathic superficial or deep recurrent staphylococcal skin infections may thus have quantitative differences in serum antistaphylococcal IgE antibodies compared with healthy dogs. "
7.	Cephalexin (Cefalexin)FDA LinkGeneric 01/01/1983 - "Cephalexin remains an effective and highly useful antibiotic for the treatment of streptococcal and staphylococcal skin infections. " 04/01/1996 - "Addition of rifampin to cephalexin therapy for recalcitrant staphylococcal skin infections--an observation." 02/01/1983 - "Treatment of staphylococcal skin infections: a comparison of cephalexin and dicloxacillin."
8.	Anti-Bacterial Agents (Antibiotics)IBA 05/30/1961 - "[Contribution to the treatment of superficial and deep skin staphylococcal infections with new antibiotics]." 07/01/2008 - "Acupuncture and moxibustion as fundamental therapeutic complements for full recovery of staphylococcal skin infection after a poor 50-day treatment response to antibiotics." 09/01/2009 - "The potential for reutericyclin derivatives to be used as topical antibiotics to treat staphylococcal skin infections was investigated. "
9.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/01/2014 - "Examples include anti-interferon (IFN)-γ autoantibodies and disseminated nontuberculous mycobacteria; anti-granulocyte macrophage colony-stimulating factor autoantibodies and cryptococcal meningitis; anti-interleukin (IL)-6 autoantibodies and staphylococcal skin infection; and anti-IL-17A, anti-IL-17F, or anti-IL-22 autoantibodies and mucocutaneous candidiasis in the setting of either APECED (autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy syndrome) or thymoma. " 12/01/2010 - "Examples include antigranulocyte macrophage-colony stimulating factor (GM-CSF) autoantibodies and pulmonary alveolar proteinosis; anti-interferon (IFN)-γ autoantibodies and disseminated nontuberculous mycobacteria (NTM); anti-interleukin-(IL)-6 autoantibodies and severe staphylococcal skin infection; anti-IL-17A, anti-IL-17F, or anti-IL-22 autoantibodies in patients with mucocutaneous candidiasis in the setting of both the autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED) syndrome and in cases of thymoma. "
10.	InterferonsIBA 01/01/2014 - "Examples include anti-interferon (IFN)-γ autoantibodies and disseminated nontuberculous mycobacteria; anti-granulocyte macrophage colony-stimulating factor autoantibodies and cryptococcal meningitis; anti-interleukin (IL)-6 autoantibodies and staphylococcal skin infection; and anti-IL-17A, anti-IL-17F, or anti-IL-22 autoantibodies and mucocutaneous candidiasis in the setting of either APECED (autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy syndrome) or thymoma. " 12/01/2010 - "Examples include antigranulocyte macrophage-colony stimulating factor (GM-CSF) autoantibodies and pulmonary alveolar proteinosis; anti-interferon (IFN)-γ autoantibodies and disseminated nontuberculous mycobacteria (NTM); anti-interleukin-(IL)-6 autoantibodies and severe staphylococcal skin infection; anti-IL-17A, anti-IL-17F, or anti-IL-22 autoantibodies in patients with mucocutaneous candidiasis in the setting of both the autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED) syndrome and in cases of thymoma. "

Therapies and Procedures

1.	Moxibustion 07/01/2008 - "Acupuncture and moxibustion as fundamental therapeutic complements for full recovery of staphylococcal skin infection after a poor 50-day treatment response to antibiotics."
2.	Drug Therapy (Chemotherapy) 01/01/2005 - "Staphylococcal skin infections in children: rational drug therapy recommendations."